Press coverage about Corium International (NASDAQ:CORI) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corium International earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.1891179566632 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Corium Internation (CORI) Secures Additional U.S. Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease (streetinsider.com)
- Corium Internation (CORI) Announces Issuance of Additional U.S. Patent for Corplex Donepezil Transdermal System for Alzheimer’s Disease (streetinsider.com)
- Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease (finance.yahoo.com)
- -$0.39 Earnings Per Share Expected for Corium International Inc (CORI) This Quarter (americanbankingnews.com)
A number of research analysts recently issued reports on CORI shares. Zacks Investment Research downgraded Corium International from a “buy” rating to a “hold” rating in a report on Thursday, April 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 price objective on shares of Corium International in a report on Tuesday, March 27th. ValuEngine upgraded Corium International from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, BidaskClub downgraded Corium International from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Corium International currently has a consensus rating of “Hold” and an average target price of $13.00.
Corium International traded up $0.24, reaching $7.94, during mid-day trading on Wednesday, Marketbeat.com reports. The company had a trading volume of 192,200 shares, compared to its average volume of 273,234. The company has a quick ratio of 7.95, a current ratio of 8.11 and a debt-to-equity ratio of 1.89. The company has a market cap of $285.95 million, a price-to-earnings ratio of -4.84 and a beta of 1.55. Corium International has a 52 week low of $7.24 and a 52 week high of $13.93.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.04). The company had revenue of $10.06 million during the quarter, compared to the consensus estimate of $7.07 million. Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. equities research analysts anticipate that Corium International will post -1.59 EPS for the current fiscal year.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.